News from aidsmap

  • T-20 expanded access study announced

    Anna Poppa | 07 November 2001

    Roche have announced plans for widening access to their experimental fusion inhibitor, T-20 (pentafuside), a new type of anti-HIV treatment. A worldwide open-label safety study, codenamed T-20 305, is ...

  • HAART for $125 a year: how can it be done?

    Keith Alcorn | 31 October 2001

    It may be possible to reduce the cost of HAART for developing countries to less than $125 a year if research into dosing and intermittent treatment can be funded, according to Dr Andrew ...

  • Treating high cholesterol in HAART patients

    Keith Alcorn | 29 October 2001

    Controversy over the risk of heart disease in people on HAART continued at the Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection last week, with competing ...

  • UK doubles commitment to Global Fund

    Julian Meldrum | 26 June 2001

    The UK's Secretary of State for International Development, the Rt Hon Clare Short MP, announced at the UN General Assembly in New York on Monday 25 September that the UK ...

  • Drug access table: June 2001 update

    Keith Alcorn | 20 June 2001

    This table updates an edition published in April to include new data on prices and discounts offered by several Indian manufacturers of generic antiretrovirals, with the brand names of their ...

  • Global drug prices: what is on offer today?

    Keith Alcorn | 20 April 2001

    This table summarises the latest information provided by companies regarding the prices at which they are currently offering antiretrovirals to resource-poor countries, and the terms of the offers. Some of these ...

  • HIV risk from single contact may be higher than thought

    Keith Alcorn | 05 March 2001

    The risk of HIV transmission from activities like unprotected anal intercourse with new partners may be dangerously underestimated by long-term studies of serodiscordant partners, a leading researcher into the sexual ...

  • Hydroxyurea debate revives: suitable drug for poor nations?

    Megan Nicholson | 05 March 2001

    The debate over the use of hydroxyurea plus ddI in the treatment of HIV disease has been revived at the World AIDS Conference, despite a study which showed that hydroxyurea ...

← Prev1...1314151617Next →

Editors’ picks from other sources

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.